Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Nov 13, 2026
MIAMI - Nov. 13, 2026 - PRLog -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP, a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, has announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018.
All ketamine injection products currently available in the U.S., having been in short supply since 2018, contain the preservative benzethonium chloride (BZT), which FDA has not determined to be generally recognized as safe and effective (GRASE) for OTC antiseptic hand rubs. NRXP injectable ketamine is preservative-free and comes in a needle-free blow-fill-seal (BFS) vial with a luer-lock tip that attaches directly to a sterile syringe. NRXP preservative free ketamine is being sold by veteran sales representatives, most of whom have decades of experience in the sterile injectable market, and who have existing relationships with purchasers controlling approximately 80% of the current US market.
Lucid Capital Markets has issued a new equity analyst report on NRXP with buy recommendation and a 12 month price target of $49 per share. The full report can be viewed at this direct link: https://www.nrxpharma.com/wp-content/uploads/2026/11/Launched-Preservative-Free-Ketamine-to-Address-Supply-Short.pdf
FDA Approval of Preservative-Free Ketamine
NRXP has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine. The approval comes ahead of the FDA-announced November 10, approval Goal Date.
"We are excited to bring Preservative-Free Ketamine to market and give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in some formulations by the US Food and Drug Administration," said Jonathan Javitt, MD, MPH, NRXP Chairman and Chief Executive Officer.
Currently available ketamine injection products all contain benzethonium chloride (BZT). According to current regulation, inactive ingredients in drugs (including preservatives) must be Generally Recognized As Safe ("GRAS") or proven to be safe. The FDA has declined to designate Benzethonium Chloride as GRAS. Under current FDA policy, benzethonium chloride cannot be included in new drugs, consumer hand cleansers, wipes, healthcare or surgical hand rubs nor in intravenous formulations above a threshold concentration for toxicological reasons.
Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
NRXP has announced completion of three Process Validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 GDUFA (Generic Drug User Fee Act) Goal Date. Process Validation is the final step in the drug manufacturing process required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).
NRXP has also completed analysis of two-year room temperature real-time stability data on preservative-free ketamine demonstrating no deterioration in purity, potency, or sterility without the need for toxic preservatives. NRXP believes that these data will be consistent with a labeled shelf life of three years or longer.
$11 Million Dollar DARPA Prime Contract Award to Evaluate Robotic Magnetic Stimulation in Conjunction with NRX-101 for Treatment of Resistant Depression
NRXP subsidiary NRx Defense Systems has announced the award of an initial $11,177,757.27 contract issued by the Defense Advanced Research Projects Agency, a Branch of the United States Department of War. The underlying clinical trial, the Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) trial has been approved by the US Food and Drug Administration and will begin enrolling patients.
The NRXP SPARC-TMS trial will be conducted at Harvard Medical School's McLean Hospital, Arizona State University, and HOPE Therapeutics. Several leading military hospitals will also be affiliated with the study.
European Patent Rights for GNK-301, a Novel Drug Candidate to Treat Amyotrophic Lateral Sclerosis (ALS)
GeNeuro, Inc., a subsidiary of NRXP has announced the award of a European Patent (EP 3 570 878 B1) entitled "Anti HERV K Envelope Antibody and Uses Thereof." The patent, together with two previously issued US patents (10,723,787 and 10,981,977) describes in detail the discovery that the envelope protein (K Env) of Human Endogenous Retrovirus K (HERV K) is found in the spinal fluid of more than 75% of people with Amyotrophic Lateral Sclerosis (ALS), is shown to be highly neurotoxic, and to produce the neurodegenerative findings of ALS.
HERVs are the remnants of viruses that infected primates between 2 and 5 million years ago and are now thought to have played a role in human disease. A monoclonal antibody against K Env (GNK-301) has been shown to block those neurotoxic effects in the same models. The patents are jointly owned by GeNeuro and the US Dept. of Health and Human Services.
The assets of the former Geneuro SA were awarded to NRXP GeNeuro, Inc. by the Courts of Switzerland in June 2026 and GeNeuro initiated manufacture of GNK-301 under Good Manufacturing Practices (cGMP) with the plan to initiate human Phase 1 trials of GNK-301 in the US and Europe in the latter half of 2027.
Commercial Sales Begun for U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage.
Certified Sales Force Providing National Coverage with Customers for Approximately 80% of Current U.S. Ketamine Sales.
Lucid Capital Markets Issued Buy Recommendation with $49 Price Target.
FDA Approval of Preservative-Free Ketamine Received Ahead of Schedule.
Ketamine, Originally Formulated in 1970 is One of the Last Remaining Sterile Drugs to Contain the Preservative Benzethonium Chloride.
Three Commercial Lots of Preservative-Free Ketamine Manufactured in Compliance with "Process Validation" Required Under FDA "Good Manufacturing Practices" (GMP).
Two-Year Stability Data Consistent with Projected Room-Temperature Stability to Three Years and Beyond with No Need for Toxic Preservatives.
$11 Million Dollar DARPA Prime Contract Award to Evaluate Robotic Magnetic Stimulation with NRX-101 Drug for Treatment of Resistant Depression,
Worldwide Generic Ketamine Market Estimated at $750 Million Per Year.
-----------------------------------------------------------------------------------------------------------------
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious central nervous system (CNS) disorders, with particular emphasis on suicidal depression, suicidal bipolar depression, PTSD and chronic pain. The company is developing therapies designed to address significant unmet medical needs, while also building HOPE Therapeutics, a clinical-care platform focused on advanced interventional psychiatric treatment.
Mission
NRx's mission is "to bring hope" through life-saving medicines for people living with unmet medical needs. The company says it seeks to use breakthrough science to make diseases that are difficult or previously untreatable more manageable, with a particular focus on bringing innovative treatments to patients with serious and life-threatening conditions.
NRx Pharmaceuticals, Inc. was legally incorporated in Delaware on September 18, 2017.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: [email protected]
Phone: (917) 653-5122
Country: United States
Disclosure listed on the CorporateAds website
Disclaimer: https://corporateads.com/disclaimer/
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc | More news from this source
Press release distribution by PRLog
More News
Will Jensen Huang’s downfall tip the scales against open-source AI?
Jensen Huang’s abrupt resignation from Nvidia has cast uncertainty over the US chip giant’s multibillion-dollar investments in open-source artificial intelligence, while potentially depriving Chinese developers of one of their most influential advocates in Washington. His departure could prompt Nvidia to scale back spending on open-weight models and their supporting infrastructure, analysts said, although strong commercial incentives would likely keep the company committed to the broader...
Jensen Huang’s Fall Costs Asia an A.I. Ambassador to the U.S.
The ex-Nvidia C.E.O. was a bridge between companies and governments. His exit will reverberate, especially in China where it could accelerate a self-reliance drive.
India road crash between bus, container truck kills 23
A head-on collision between a container truck and a passenger bus killed at least 23 people, including three children, in eastern India on Friday, a police official said The crash took place on a highway bordering Kaziranga National Park in the northeastern state of Assam. The road is a designated animal corridor, where strict speed limits are in place. “The total number of casualties is 23,” said Swapneel Deka, the local district police chief. Assam Chief Minister Himanta Biswa Sarma said he...
China could tighten rare earths exports if US escalates chip curbs over Nvidia: analysts
China could retaliate with tighter rare earth export controls if Washington further restricts chip sales in the wake of the Nvidia saga, Chinese analysts say, though they expect broader US-China trade talks to remain on track ahead of a planned meeting between the two countries’ leaders next week. Following Jensen Huang’s resignation from Nvidia on Thursday amid reports of multiple extramarital affairs, attention now turns to whether Washington will further tighten semiconductor export controls...
Malaysia turns to Turkey for warship missiles after Norway’s export freeze
Malaysia’s decision to pivot to Turkey for anti-ship missiles after Norway cancelled a procurement deal has offered it a way out of a costly setback, though analysts warn the episode has exposed its vulnerability to foreign export controls and highlighted the need for greater defence autonomy. The planned switch to Turkey’s Roketsan Atmaca missile system for the Malaysian navy’s littoral combat ships (LCS) reflects Kuala Lumpur’s growing defence ties with Ankara, even as questions remain over...
Jensen Huang’s exit tests Nvidia’s supply chain clout, ability to bankroll AI buildout
For years, Jensen Huang was more than Nvidia’s CEO – he was a key figure driving the artificial intelligence boom, parlaying close ties with Asian chip foundries and aggressive financial backing into an unprecedented global buildout of data centres. Following his sudden resignation, the industry is confronting two immediate questions: without Huang’s personal relationships in Taiwan and South Korea, can Nvidia defend its priority access to scarce chipmaking and memory supply? And will it...
Indonesia’s upper house to pick new VP on December 2
Indonesia’s upper house of parliament will pick the country’s new vice-president on December 2, its speaker said on Friday, after the dramatic resignation of Gibran Rakabuming Raka, the president’s deputy and the son of his predecessor. Gibran’s resignation this week, which analysts say could widen the gulf between President Prabowo Subianto and former president Joko Widodo, followed a month of increasing political pressure from lawmakers after Indonesia’s top courts ruled that he had...
After Xi Purges China’s Generals, a Military Inquisitor Rises
The rise of Zhang Shengmin suggests that China’s top brass remains embroiled in investigations, potentially complicating preparations for war over Taiwan.
Could Nvidia scandal put Malaysia’s AI boom in US crosshairs?
A scandal involving Nvidia founder Jensen Huang and an alleged Chinese spy is putting Malaysia’s booming data centre industry in Washington’s crosshairs, as US lawmakers demand tighter controls on advanced artificial intelligence chips. Malaysia is among the Southeast Asian economies facing potential fallout from the controversy surrounding Singapore-based Nvidia chip buyer Megaspeed and its Malaysian subsidiary Speedmatrix, amid concerns that American technology may have been diverted to...
Jensen Huang quits, China trade surplus hits US$1 trillion, Xi-Trump summit
Jensen Huang resigned as chief executive officer of chipmaker Nvidia following an affair with an alleged Chinese spy, boosting the odds of tighter US export controls against China days before the countries’ leaders are due to meet. Huang left the company he founded in 1993 with immediate effect, according to a statement on Thursday. Chief Financial Officer Colette Kress will act as interim chief executive while the board looks for a permanent replacement to head the world’s second-biggest...
Jensen Huang’s fall sparks dismay in Asia over Nvidia ex-CEO’s family man image
Tech titan Jensen Huang, dressed in his signature leather jacket, has always carried the charisma of a rock star during his public appearances around the world. That allure runs deep in South Korea, where he has had viral dinners at local fried chicken joints as onlookers jostled for a glimpse of the AI chip visionary. But that admiration turned to dejection for some fans in the East Asian nation after Nvidia announced on Thursday that Huang had resigned as CEO amid reports of three extramarital...
Court-appointed administrators to sound out investors for Nexperia stake amid Wingtech feud
The two court-appointed administrators overseeing Nexperia said on Thursday they would sound out investors on a majority or minority stake in the Dutch chipmaker, a week after its Chinese owner Wingtech rejected their proposal to hand control of its operations outside China to foreign investors. “We have decided to assess market interest in possible long-term solutions for Nexperia,” Guido Dierick and Arnold Croiset van Uchelen said in a statement. “No decision has currently been taken to reduce...
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.